28 Nov 2014 12:55
The following amendment has been made to the 'Director's Dealing' announcement released on 28 November 2014 at 10:35 under RNS No 3090Y.
Mr. Shepherd's shareholding increased to 2,708,180, his percentage interest remains at 2.5 per cent.
All other details remain unchanged.
The full amended text is shown below.
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Director's Dealing
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that Andrew Shepherd, Chief Executive Officer of the Company, today purchased 30,974 ordinary shares in the Company at 17p per share through his SIPP.
Following this transaction, Mr. Shepherd's total beneficial holding has increased to 2,708,180 ordinary shares representing 2.5 per cent. of the issued ordinary share capital of the Company.
Contacts:
Omega Diagnostics Group PLC | Tel: 01259 763 030 or www.omegadiagnostics.com |
Andrew Shepherd, Chief Executive | |
Kieron Harbinson, Group Finance Director Jag Grewal, Group Sales and Marketing Director | |
finnCap Ltd | Tel: 020 7220 0500 |
Geoff Nash/Christopher Raggett (Corporate Finance) Mia Gardner (Corporate Broking) | |
Walbrook PR Limited | Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus | Mob: 07980 541 893 |
Lianne Cawthorne | Mob: 07584 391 303 |
ODX.L (ODX)